Gapping down
In reaction to earnings/guidance: XENT -23.9%, GUID -21.5%, FEYE -18.4%, BLUE -17.9%, ALR -14.5%, CSLT -14.2%, LCI -14.1%, AVG -14%, FRSH -12%, ACLS -11.8%, MGA -8.2%, G -7.4%, CF -7.3%, WAC -7.3%, WFM -7.2%, ETP -7.1%, EPAM -6.9%, TUMI -6.2%, ENVA -5.8%, LPSN -5.4%, MBI -5.4%, CSTM -5.4%, ANDE -5.1%, QCOM -5%, PDLI -4.7%, ESI -4.7%, ATHM-4.6%, ZUMZ -4.1%, RLYP -3.4%, XNPT -3.3%, SEAS -3.2%, HOLX -3.1%, RGR -2.8%, VVUS -2.6%, RIG -2.6%, MET -2.6%, VER -2.3%, SBAC -2.2%, TWO -2.2%, FNHC -1.9%, HDP -1.8%, FUEL -1.8%, (appoints Randy Wootton as CEO), BKCC -1.7%, SFY -1.7%, SPPI -1.1%, (Eagle Pharma and Spectrum Pharmaceuticals (SPPI) enter into a co-promotion agreement for six Eagle products; Eagle to pay Spectrum a base fee of $12.8 mln and potential milestones), INOV -1.1%, SQNM -1.1%, WMGI -1%, PEIX -1%
Other news: LCI -14.1% (discloses update on pending acquisition of Kremers Urban Pharmaceuticals regarding transition of one of its customers), AVG -14% (announces that John Little will transition from his role as Chief Financial Officer), SABR -1.7% (announces the secondary public offering of 30 mln shares of common stock by existing stockholders; Co will repurchase ~$100 mln of the 30 mln shares from the underwriter), SPPI -1.1% (Eagle Pharma and Spectrum Pharmaceuticals (SPPI) enter into a co-promotion agreement for six Eagle products; Eagle to pay Spectrum a base fee of $12.8 mln and potential milestones), TVPT -0.9% ( files mixed securities shelf offering), VLRS -0.9% (reported October traffic)
Analyst comments: AVP -2.3% (downgraded to Sell from Neutral at UBS ), DYAX -0.9% (downgraded to Hold from Buy at Needham
In reaction to earnings/guidance: XENT -23.9%, GUID -21.5%, FEYE -18.4%, BLUE -17.9%, ALR -14.5%, CSLT -14.2%, LCI -14.1%, AVG -14%, FRSH -12%, ACLS -11.8%, MGA -8.2%, G -7.4%, CF -7.3%, WAC -7.3%, WFM -7.2%, ETP -7.1%, EPAM -6.9%, TUMI -6.2%, ENVA -5.8%, LPSN -5.4%, MBI -5.4%, CSTM -5.4%, ANDE -5.1%, QCOM -5%, PDLI -4.7%, ESI -4.7%, ATHM-4.6%, ZUMZ -4.1%, RLYP -3.4%, XNPT -3.3%, SEAS -3.2%, HOLX -3.1%, RGR -2.8%, VVUS -2.6%, RIG -2.6%, MET -2.6%, VER -2.3%, SBAC -2.2%, TWO -2.2%, FNHC -1.9%, HDP -1.8%, FUEL -1.8%, (appoints Randy Wootton as CEO), BKCC -1.7%, SFY -1.7%, SPPI -1.1%, (Eagle Pharma and Spectrum Pharmaceuticals (SPPI) enter into a co-promotion agreement for six Eagle products; Eagle to pay Spectrum a base fee of $12.8 mln and potential milestones), INOV -1.1%, SQNM -1.1%, WMGI -1%, PEIX -1%
Other news: LCI -14.1% (discloses update on pending acquisition of Kremers Urban Pharmaceuticals regarding transition of one of its customers), AVG -14% (announces that John Little will transition from his role as Chief Financial Officer), SABR -1.7% (announces the secondary public offering of 30 mln shares of common stock by existing stockholders; Co will repurchase ~$100 mln of the 30 mln shares from the underwriter), SPPI -1.1% (Eagle Pharma and Spectrum Pharmaceuticals (SPPI) enter into a co-promotion agreement for six Eagle products; Eagle to pay Spectrum a base fee of $12.8 mln and potential milestones), TVPT -0.9% ( files mixed securities shelf offering), VLRS -0.9% (reported October traffic)
Analyst comments: AVP -2.3% (downgraded to Sell from Neutral at UBS ), DYAX -0.9% (downgraded to Hold from Buy at Needham